X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%
Tue, 12 Feb

AUROBINDO PHARMA has announced its results for the quarter ended December 2018. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-17*
3
Sep-18*
3
Dec-18*
QoQ ChangeYoY Change
Net SalesRs m43,36147,51452,69710.9%21.5%
Other incomeRs m331263639143.1%93.2%
TurnoverRs m43,69247,77753,33511.6%22.1%
ExpensesRs m33,10537,65141,83311.1%26.4%
Gross profitRs m10,2589,59410,61310.6%3.5%
DepreciationRs m1,3811,6371,631-0.3%18.1%
InterestRs m18935447734.6%152.7%
Profit before taxRs m9,0207,8669,14416.2%1.4%
TaxRs m3,0691,7542,04816.7%-33.3%
Profit after taxRs m5,9506,1127,09616.1%19.3%
Gross profit margin%23.720.220.1
Effective tax rate%34.022.322.4
Net profit margin%13.612.813.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 21.5% on a year-on-year (YoY) basis. The expenses were up by 26.4% YoY during the same period.
  • The company's operating profit increased by 3.5% YoY during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 23.7% in 3QFY18.
  • Depreciation charges increased by 18.1% and finance costs increased by 152.7% YoY, respectively.
  • Other income increased by 93.2% YoY during the quarter.
  • Net profit for the quarter increased by 19.3% YoY. Net profit margins during the quarter declined from 13.6% in 3QFY18 to 13.3% in 3QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 10.9% on a quarter-on-quarter (QoQ) basis. The expenses were up by 11.1% QoQ during the same period.
  • The company's operating profit declined by 10.6% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 20.1% in 3QFY19 as against 20.2% in 2QFY18.
  • Net profit for the quarter increased by 16.1% QoQ, while net profit margins increased from 12.8% in 2QFY18 to 13.3% in 3QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 607.9 to Rs 766.0, registering a Gain of Rs 158.2 or around 26.0%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,712.7 (down 0.1%). Over the last one year it has moved down from 14,517.2 to 13,712.7, a gain of 805 points (down 5.5%).

Overall, the S&P BSE SENSEX is up 6.1% over the year.

Current Valuations

At the current price of Rs 766.0, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 19.5 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.8 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Best 4 Small-cap Stocks to Buy(The 5 Minute Wrapup)

Jun 3, 2019

In the sometimes good sometimes bad market of small caps, there are strong buying opportunities available today. But this great opportunity won't last forever.

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Top 7 Stocks to Profit from Modi's Repeat Performance(Profit Hunter)

Jun 3, 2019

The long-term India story looks promising with the Modi government back in power. Which stocks are likely to go up the most?

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 14, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - PANACEA BIOTECH COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS